Approvals and designations made by the U.S. Food and Drug Administration for the week ended Jan. 11.
|FDA headquarters in Silver Spring, Md.|
|Source: Associated Press|
* Grifols SA's Erytra Eflexis, to analyze the compatibility of blood between transfusion recipients and donors.
* Novartis AG's crizanlizumab, to prevent vaso-occlusive crises in patients with sickle cell disease. Novartis said it plans to file for FDA approval of the drug, also known as SEG101, in the first half of 2019.